Consumers in the U.S. are not aware that they pay up to twice as much as consumers in other countries for brand-name medicines because of the lack of transparency in the U.S. pricing system, according to a studies in Health Affairs. The University of Michigan's Erik Gordon said real prices are extremely difficult to find because they are "confusing and camouflaged." Evidence-based systems can lead to lower drug costs, one of the studies found.

Related Summaries